Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index; 26 of the 49 sources its claims cite were checked for support.

A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults

Open access
McGowan, Barbara, Ciudin, Andreea, Baker, Jennifer L., Busetto, Luca, Dicker, Dror, Frühbeck, Gema, Goossens, Gijs H., Monami, Matteo, Sbraccia, Paolo, Martinez-Tellez, Borja, Woodward, Euan, Yumuk, Volkan · 2025 · Nature Medicine

Published version of a preprint

Abstract

This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide. Both tirzepatide and semaglutide showed normoglycemia restoration, remission of type 2 diabetes and reduction in hospitalization due to heart failure. Semaglutide was effective in reducing major adverse cardiovascular events and reducing pain in knee osteoarthritis. Tirzepatide was effective in remission of obstructive sleep apnea syndrome and metabolic dysfunction-associated steatohepatitis. These results support the need to individualize the selection of OMMs.

Overview

CoChat Summary

## TL;DR

This systematic review and network meta-analysis of 56 RCTs (60,307 adults) found that all included obesity medications produced greater total body weight loss than placebo, with semaglutide and tirzepatide generally showing the largest effects. Beyond weight loss, some agents showed complication-specific benefits, including semaglutide for MACE and knee osteoarthritis pain, and tirzepatide for obstructive sleep apnea and MASH.

## Key findings

  • Across 56 RCTs / 60 comparisons enrolling 60,307 patients, all obesity management medications (OMMs) had significantly greater TBWL% than placebo at the endpoint (55 comparisons; no evidence of inconsistency, H = 1.51).
  • Only semaglutide and tirzepatide achieved estimated TBWL% greater than 10% at the endpoint; at 52 weeks, all treatments except orlistat were significantly better than placebo, and only semaglutide and tirzepatide reached at least 10% TBWL.
  • In the full analysis, only tirzepatide was associated with a greater proportion of patients achieving at least 25% TBWL (odds ratio 33.8 [18.4–61.9], P < 0.001).
  • Complication-specific benefits included: semaglutide lowering MACE risk and all-cause mortality, tirzepatide reducing HHF, semaglutide and tirzepatide improving glycemic outcomes in prediabetes/T2D, semaglutide improving knee osteoarthritis outcomes, and tirzepatide improving OSAS and MASH outcomes.

## Methods

  • Systematic review and network meta-analysis reported under PRISMA; Medline and Embase were searched up to 31 January 2025.
  • Included placebo-controlled or active-controlled RCTs in adults (≥18 years) with obesity (BMI ≥ 30 kg m−2) or overweight (BMI > 25 kg m−2), with treatment duration of at least 48 weeks, evaluating orlistat, phentermine plus topiramate, naltrexone plus bupropion, liraglutide, semaglutide, or tirzepatide.
  • Primary endpoint was TBWL% at the end of the trial; analyses used random-effects models, network meta-analysis for outcomes with at least 10 RCTs, traditional meta-analyses or descriptive synthesis for sparser outcomes, plus risk-of-bias assessment and GRADE.

## Limitations

  • The paper states that heterogeneity in study populations (baseline BMI, age, obesity-related complications) may influence treatment effects, and that limited data were available for people with BMI ≥ 40 kg m−2, the elderly, adolescents, and people with overweight.
  • Most trials were placebo-controlled, limiting head-to-head comparisons, and differing lifestyle intervention intensity in placebo groups may have affected comparative results.
  • Many trials lacked comprehensive reporting for key outcomes, and data on weight maintenance, metabolic effects, and serious adverse events beyond 2 years were scarce.
  • The paper also notes potential inconsistency in the NMA and limited subgroup reporting; additionally, the evidence base was restricted to RCTs and did not include lifestyle or bariatric surgery studies (evident from the text).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41591-025-03978-z

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Graphical representations of networks of interventions. Graphical representation of the geometry of all networks of interventions with respect to TBWL% at the endpoint (a), 52 weeks (b) and 53–104 weeks (c).
Fig. 1 Graphical representations of networks of interventions. Graphical representation of the geometry of all networks of interventions with respect to TBWL% at the endpoint (a), 52 weeks (b) and 53–104 weeks (c).CC BY-NC-ND · PubMed Central
Fig. 2 Network forest plots. Network forest plots showing the effects of each OMM on TBWL% at the endpoint (a), 52 weeks (b) and 53–104 weeks (c).
Fig. 2 Network forest plots. Network forest plots showing the effects of each OMM on TBWL% at the endpoint (a), 52 weeks (b) and 53–104 weeks (c).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

14 Valid · 8 Not valid · 15 Not checked · 80 Own results and interpretations

51 more claims · 3 with their cited sources checked

Create a free account to see all 117 claims and to verify the 5 references still open.

See all claims — free account
  • It may state two separate claims as one. 50
  • Probably not a substantial claim. 17

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 75 references

Cited by

See all 100

Metadata

Authors
McGowan, B., Ciudin, A., Baker, J. L., Busetto, L., Dicker, D., Frühbeck, G., Goossens, G. H., Monami, M., Sbraccia, P., Martinez-Tellez, B., Woodward, E., & Yumuk, V.
Affiliations
  • Universitat Autònoma de Barcelona (ES)
  • University of Padua (IT)
  • Maastricht University Medical Centre (NL)
  • University of Rome Tor Vergata (IT)
  • Istanbul University-Cerrahpaşa (TR)
Corresponding author
McGowan, Barbara
Venue
Nature Medicine
Published
2025-10
Volume
31
Issue
10
Pages
3317-3329
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4414747615
Cited by
100
References
75
Citations by year
2026: 91 · 2025: 9
FWCI
13.42
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by-nc-nd)
  • Research Square (acceptedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, cc-by-nc-nd)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion, cc-by-nc-nd)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc-nd)
  • Padua Research Archive (University of Padova) (submittedVersion, cc-by-nc-nd)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Regeneron Pharmaceuticals
  • European Foundation for the Study of Diabetes
  • Novo Nordisk
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
anti-obesity drugs, obesity treatment, weight loss, orlistat, semaglutide, liraglutide, tirzepatide, naltrexone/bupropion, phentermine/topiramate, type 2 diabetes remission, cardiovascular events, heart failure hospitalization, obstructive sleep apnea, nonalcoholic steatohepatitis, adverse events, lipid profile, glycemic control
MeSH terms
Liraglutide, Semaglutide, Adult, Glucagon-Like Peptides, Humans, Obesity, Quality of Life, Weight Loss, Randomized Controlled Trials as Topic, Treatment Outcome, Anti-Obesity Agents, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. https://app.cochat.ai/papers/10.1038/s41591-025-03978-z
The paper
McGowan, B., Ciudin, A., Baker, J. L., Busetto, L., Dicker, D., Frühbeck, G., Goossens, G. H., Monami, M., Sbraccia, P., Martinez-Tellez, B., Woodward, E., & Yumuk, V. (2025). A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nature Medicine. https://doi.org/10.1038/s41591-025-03978-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.